Loki Home

Research Interests

Funding Opportunities

FAQ

UI Login Guest Login

Browse by Investigator Last Name



Browse Research


Photo of David Lubaroff

David Lubaroff

Professor,  Urology

Contact Information

Laboratory
3210 MERF
Iowa City, IA 52242

Phone: +1 319 335 8423
Email: david-lubaroff@uiowa.edu
Web:

Education

PhD, Yale University

Appointments

Primary: Urology
Secondary: Microbiology

Centers and Program Affiliations

Interdisciplinary Graduate Program in Immunology

Research Interests

clinical trial, immunotherapy, prostate cancer, vaccine

MeSH Terms from Publications

Prostatic Neoplasms, Rats, Animals, Rats, Inbred Lew, Lymph Nodes, Adenocarcinoma, T-Lymphocytes, Male, Cancer Vaccines, Rats, Inbred Strains, Prostate-Specific Antigen, Neoplasms, Experimental, Ovarian Neoplasms, Transplantation, Homologous, Rats, Inbred BUF, Hypersensitivity, Delayed, Skin Transplantation, Radiation Effects, Isoantigens, Bone Marrow Cells, Humans, Lymphocytes, Histocompatibility Antigens, Thymus Gland, Neoplasm Transplantation

Research Summary

The work in the Lubaroff concentrates on the area of tumor immunology with an emphasis on immunotherapy. We have constructed microbial vaccines to be used for the investigation of gene and immunotherapy of prostate cancer. Investigations on the ability of immunized animals to produce immune responses to the transgene product induced by the vaccine are underway. Both in vitro and in vivo experiments are being carried out, the latter studies involve the destruction of tumors following immunization of animals with the prostate cancer vaccine. The mechanisms of tumor rejection induced by the vaccines are being studied using methodologies to deplete specific cell populations, and by the use of transgenic mice. We are also investigating the ability of unmethylated CpG oligodinucleotides to augment the anti-tumor immune responses. Additionally, we are carrying our "translational" research in the form of clinical trials of our adenovirus vaccine in men with prostate cancer. Important in these trials is the safety of the vaccine and its ability to induce anti-tumor immunity. We have recently completed a Phase I clinical trial of the vaccine that demonstrated its safety. We have evaluated the immunity induced by the vaccine using measures of antibodies, cytotoxic T lymphocytes, and number of antigen-specific T cells using both intracellular cytokine staining and ELISPOT analysis. A therapeutic Phase II trial will begin shortly. Finally, we have been collaborating on studies of psychosocial effects on immune status in cancer patients.

Recent Publications


Show publications
  1. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun 26(7):1037-44, 2012. [PubMed]
  2. Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol 30(23):2885-90, 2012. [PubMed]
  3. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 11(7):857-68, 2012. [PubMed]
  4. Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. Mol Pharm 8(5):1652-61, 2011. [PubMed]
  5. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother 60(9):1309-17, 2011. [PubMed]
  6. Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse. Prostate Cancer Prostatic Dis 14(2):118-21, 2011. [PubMed]
  7. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25(2):250-5, 2011. [PubMed]
  8. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun 24(8):1231-40, 2010. [PubMed]
  9. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer 116(18):4410-9, 2010. [PubMed]
  10. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 15(23):7375-80, 2009. [PubMed]